Abstract
Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the risks by taking appropriate preventative actions to help inform therapeutic decisions, promote rational use of medicines, guide risk management and communications is gradually growing but yet to be fully optimized.This study sought to assess the current status of pharmacovigilance in Sierra Leone since it became the 87th member of the World Health Organisation International Drug Monitoring Programme. This study evaluated the pharmacovigilance system in Sierra Leone through a comprehensive and system-based approach that covered the national medicines regulatory authority, health facilities and public health programmes. A descriptive cross-sectional study design was employed. Using a convenience sampling method, 14 respondents from the national medicines regulatory authority, six health facilities and six public health programmes were interviewed.Data were collected using a validated metric instrument: Indicator-Based Pharmacovigilance Assessment Tool. A scoring system was used for the quantification of assessment results with a score greater than 60% indicating that an organization has structural and policy frameworks to collect and collate safety data in a national database and evaluate the risks and benefits by both active and passive approaches.The study findings showed that the national medicines regulatory authority scored 79% and thus met the standard requirements of pharmacovigilance. On the other hand, the health facilities and public health programmes scored less than 60% indicating the need to fully operationalise pharmacovigilance frameworks at these levels. The study further demonstrated that the national medicine regulatory authority which hosts the national pharmacovigilance centre had functional pharmacovigilance structures and processes with potential to providing leadership in the implementation of pharmacovigilance in Sierra Leone.
Highlights
The definition and scope of pharmacovigilance (PV) has evolved over the years to accommodate systems approach for improving the safe use of medicines
The performance by pharmacovigilance (PV) area is as follows (Table 1): The findings of the study revealed that the required policy statements for policy, law, and regulation for PV in Sierra Leone was in place but no specific legislation for PV was available
From the risk management and communication perspective, this study showed that the PV centre requires marketing authorisation holders (MAHs) to have risk mitigation plans (RMP) for high-risk medicines so as to prevent and manage Adverse Drug Reaction (ADR) by averting serious known risks
Summary
The definition and scope of pharmacovigilance (PV) has evolved over the years to accommodate systems approach for improving the safe use of medicines. The World Health Organisation (WHO) has defined pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of. A comprehensive PV system involves more than just risk identification and data collection. It takes into consideration risk evaluation, minimisation and communication. Such systems protect the public from medicinerelated harms through efficient and timely detection, reporting, assessment, communication and prevention of medicine-related adverse events through people and. Like the WHO and its PV collaborating centres in Uppsala, Rabat, Lareb, Accra and India and the United States Pharmacopeia/Promoting the Quality of Medicines (USP/PQM) programme are providing financial and capacity building support to build PV systems in settings were resources are scarce [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
